The COVID-19 pandemic has led to an urgent response from the research and scientific community around the world. The scientific community needs innovative tools that enable rapid development of COVID-19 diagnostics, therapeutics, and vaccines. Synthego is supporting this effort by utilizing our integrated and industrialized genome engineering factories to quickly and effectively translate the findings from recent SARS-CoV-2 reports into effective research tools.

SARS-CoV-2 Guide RNAs

Synthego Advanced RNA Series

Guide RNAs that target the SARS-CoV-2 RNA genome, available for either Cas13a (viral detection) or Cas13d (in vivo viral targeting). For convenience, we used some bioinformatics to produce a list of 50 optimized guide RNAs from over 80 SARS-CoV-2 RNA sample submissions to the Virus Pathogen Resource.

Inspired by the early work of Prof. Feng Zhang and collaborators at The Broad Institute and MIT who published Cas13a CRISPR-based diagnostic test to identify the virus (Protocol) and Prof. Stanley Qi’s lab who developed a Cas13d CRISPR-based potential therapeutic approach. For a great primer on how you can get started working with Cas13, please check out this incredibly helpful tips and tricks from Feng Zhang’s lab.

SARS-CoV-2 Human Interactome Gene Knockout Kit

Synthego Gene Knockout Kit v2

The Gene Knockout Kit v2 implements a novel multi-guide strategy that consists of up to three spatially coordinated modified sgRNAs that induce fragment deletions. Powered by Synthego’s smart informatics, our design tool generates custom multi-guide sgRNA designs that reliably knock out any human protein-coding gene, including the SARS-CoV-2  Interactome genes, on the first try.

SARS-CoV-2 Interactome Library

Pre-defined Arrayed CRISPR sgRNA gene knockout library targeting 330 human proteins known to interact with SARS-CoV-2 viral proteins. Gain insights into the molecular mechanisms behind the pathogenesis of the novel coronavirus. Designed with Synthego’s proprietary multi-guide design for optimal knockout efficiency.

Druggable SARS-CoV-2 Interactome Library

Pre-defined Arrayed CRISPR sgRNA gene knockout library targeting 63 druggable human proteins known to interact with SARS-CoV-2 viral proteins. Gain insights into potential therapeutic targets for the novel coronavirus. Designed with Synthego’s proprietary multi-guide design for optimal knockout efficiency.

We were inspired to develop a series of CRISPR gene knockout tools for perturbing proteins that interact with the virus after reviewing a recent pre-print in BioRxiV “A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.” This was a multi-institutional research effort led by Prof. Nevan Krogan of UCSF.

We hope this allows researchers to systematically determine the functional relevance of these interactions and conduct validation screens for antiviral therapeutics that target druggable genes.

Updates on CRISPR-Cas13 for possible SARS-CoV-2 Therapeutic Development

Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza

Authors: Timothy R. Abbott, et al. Link to paper: https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00736.pdf

Journal/ Pre-Print: Cell (pre-proof of accepted peer-reviewed article)

Treating Influenza and SARS-CoV-2 via mRNA-encoded Cas13a

Arthors: Emmeline L Blanchard, et al. Link to paper: https://www.biorxiv.org/content/10.1101/2020.04.24.060418v1.full.pdf